Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...

Moderator: Michael Ryan, J.D., Partner, McDermott Will & Emery Panel Participants: Castle is also a member of the City of Phoenix and Texas delegations attending BIO 2025. For information on Castle, ...

Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific ...

SOMERSET, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution, a global leader in the comparator sourcing and clinical trial supplies, has launched NCE Grid, the world’s first free NCE-1 ...

The MNPR-101 EAP is now open for enrollment to patients with advanced solid tumors at EDNOC in Houston, Texas. EDNOC is among the first private outpatient facilities in the U.S. to be designated as a ...

Pharmazz, Inc. ("Pharmazz" or the "Company"), a late-stage biopharmaceutical company developing innovative therapies for unmet medical needs in critical care and neurology, has announced a $25 million ...

Oxford, UK – 11 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, provides an update to coincide with its Annual General Meeting being held at ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 9, 2025 at 10 a.m. Eastern Time at the Harvard Club. The ...

Dr. James Lee is a Clinician Scientist Group Leader at the Francis Crick Institute (London, UK) and an Honorary Consultant Gastroenterologist at the Royal Free Hospital. He has clinical expertise in ...

As payment processing costs continue to rise, healthcare providers face continuous pressure on operating margins. LQpay’s enhanced surcharging platform offers a powerful, compliant way for practices ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that its next-generation PSMA-PET imaging 1 agent for prostate cancer, Gozellix® (kit for the preparation ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...